ReST THERAPEUTICS

ReST's MISSION is to bring FENM, a proprietary molecule targeting NMDA receptor, to First in Human then Clinical Proof of Concept for PTSD and Alzheimer. With 50 million people affected and a market expected to reach 14.9b$ by 2026, Alzheimer's disease and Alzheimer's-related dementias are two of the key challenges for Healthcare in the 21st century. Over 150 million people might still be affected by 2050. ReST Pharmaceuticals has been developing FENM (Fluoroethylnormemantine), initially designed as a biomarker for NMDA receptor (a key target for AD) mimicking the structure of Memantine (ebixa®), the sole marketed drug partly efficient for moderate to severe forms of AD. Tested in several animal models against Memantine, FENM has demonstrated, not only a higher efficacy for cognitive preservation and protection against neurotoxicity generated by beta-amyloid peptide, but none of the contrary effects of Memantine, effects which preclude the use of Memantine at the doses required to generate clinical neuroprotection. The risk of failure of FENM development is thus significantly lowered. Additionally, building a strong network of academic partners, ReST has been able to acquire evidences that the effect of FENM on NMDA should allow a full recovery from traumatic stress, paving the way for a development as a secondary prophylactics for PTSD. This second high-risk/high-impact target will allow a faster route to the market and pave the way for the PII in AD. The initial Clinical POC in PTSD will target the recovery following assault. ReST IP proprietary FENM platform is protected by 3 patents series (one already granted internationally, one granted in France and pending internationally, one recently applied). ReST has secured a Seeding of 2M€ and is actively working on the regulatory development paving the fastest route to FIH to be reached by 2023.